Figure 3.

Example of a patient with advanced HNSCC who was investigated with ¹⁸F-FDG PET at staging (A) and after the end of combined chemoradiotherapy (B). Before treatment the patient underwent ⁶⁴Cu-ATSM PET/CT (C-E), documenting intense tracer uptake (SUV_max 17.86) both in the primary tumor, involving the right tonsil, and in numerous bilateral cervical nodes. Despite the high-dose therapeutic regimen utilized, the patient presented some residual disease at end-of-treatment evaluation (B), as confirmed during follow-up.